Zimmer Biomet Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Zimmer Biomet Holdings şirketinin toplam hissedar öz sermayesi $12.4B ve toplam borcu $6.6B olup, bu da borç-öz sermaye oranını 53.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $21.7B ve $9.3B dir. Zimmer Biomet Holdings 'in FAVÖK'ü $1.6B faiz karşılama oranı 7.7 dur. Şirketin $569.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

53.6%

Borç/özkaynak oranı

US$6.64b

Borç

Faiz karşılama oranı	7.7x
Nakit	US$569.00m
Eşitlik	US$12.38b
Toplam yükümlülükler	US$9.34b
Toplam varlıklar	US$21.72b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: Z1BH34 'nin kısa vadeli varlıkları ( $4.9B ) kısa vadeli yükümlülüklerini ( $3.6B ) aşıyor.

Uzun Vadeli Yükümlülükler: Z1BH34 'un kısa vadeli varlıkları ( $4.9B ) uzun vadeli yükümlülüklerini ( $5.8B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: Z1BH34 'nin net borç/öz sermaye oranı ( 49% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: Z1BH34 'nin borç/öz sermaye oranı son 5 yılda 69.1% seviyesinden 53.6% seviyesine düştü.

Borç Kapsamı: Z1BH34 'nin borcu işletme nakit akışı ( 23.8% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: Z1BH34 'in borcuna ilişkin faiz ödemeleri EBIT ( 7.7 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Zimmer Biomet Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Ending December 31, 2024

Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Zimmer Biomet Holdings, Inc. Appoints David Demartino as Senior Vice President, Investor Relations

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024, Payable on or About October 31, 2024

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2024

Zimmer Biomet Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announces an Equity Buyback for $2,000 million worth of its shares.

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024, Payable on or About July 31, 2024

Zimmer Biomet Holdings, Inc. Reiterates Financial Guidance for Current Full-Year 2024

Zimmer Biomet Holdings, Inc. to Report Q1, 2024 Results on May 02, 2024

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration (FDA) 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024

Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Zimmer Biomet Holdings, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Zimmer Biomet Holdings, Inc. Approves Cash Dividend for the Fourth Quarter of 2023, Payable on or About January 31, 2024

Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023

Zimmer Biomet Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zimmer Biomet Holdings, Inc. Announces Quarterly Dividend for Third Quarter of 2023, Payable on or about October 31, 2023

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year 2023

Zimmer Biomet Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023, Payable on July 31, 2023

Zimmer Biomet Holdings, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) entered into a definitive agreement to acquire Embody, Inc. for approximately $300 million.

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022, Payable on or About January 31, 2023

Zimmer Biomet Holdings, Inc. Expands Persona(R) Knee System Portfolio with FDA Clearance of Persona(R) Osseoti(R) Keel Tibia for Cementless Knee Replacement

Zimmer Biomet Holdings, Inc. Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Zimmer Biomet Holdings, Inc. Receives FDA Clearance for Identity(TM) Shoulder System for Shoulder Replacement

Zimmer Biomet Holdings, Inc Approves Quarterly Cash Dividend, Payable on or About October 31, 2022

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Zimmer Biomet Holdings, Inc. Appoints Keri P. Mattox as Chief Communications and Administration Officer

Zimmer Biomet Holdings, Inc. Approves Quarterly Dividend for Second Quarter of 2022, Payable on or About July 29, 2022

Zimmer Biomet Holdings, Inc. Debuts First-Of-Its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

Extremity Medical, LLC Files Patent Infringement Lawsuit Against Nextremity Solutions, Zimmer Biomet Holdings, Inc. and Zimmer, Inc

Zimmer Biomet Holdings, Inc. to Report Q1, 2022 Results on May 03, 2022

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 16, 2022

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. Announces New Data Supporting Clinical Benefits of Mymobility® with Apple Watch® At AAOS 2021

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2021

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Year Ending December 31, 2021

Zimmer Biomet Holdings, Inc. Announces Management Changes

Zimmer Biomet Holdings, Inc. Approves Quarterly Cash Dividend for the First Quarter of 2021, Payable on or About April 30, 2021

Zimmer Biomet Holdings, Inc. Announces Board Changes

Zimmer Biomet Holdings, Inc Appoints Vafa Jamali as CEO of 'NewCo'

Zimmer Biomet Holdings, Inc. Appoints Ellison (Ellie) M. Humphrey as Chief Transformation Officer

Zimmer Biomet Holdings, Inc. to Report Q4, 2020 Results on Feb 05, 2021

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) acquired A&E Medical Corporation from Vance Street Management LLC and others for approximately $250 million.

Zimmer Biomet Holdings, Inc. Announces Preliminary Results from mymobility® Clinical Study at 2020 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. to Report Q3, 2020 Results on Nov 06, 2020

Zimmer Biomet Holdings, Inc. to Report Q3, 2019 Results on Nov 05, 2019

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) completed the acquisition of remaining 41.18% stake in MedTech Société Anonyme from Bertin Nahum, Bpifrance Investissement and other shareholders.

Zimmer Biomet Holdings, Inc. Does Not Provide Updated Financial Guidance for 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin